Levels of adiponectin, C-reactive protein and interleukin-1 receptor antagonist are associated with the relative change in body mass index between childhood and adulthood

Diabetes and Vascular Disease Research

Volumn 4, Issue 4, 2007, Pages 328-331

  Saltevo, Juha ^a   Vanhala, Mauno ^a,b,c   Kautiainen, Hannu ^d   Laakso, Markku ^e  

^a Central Hospital of Middle Finland   (Finland)

^b Laukaa Health Center   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

^d RHEUMATISM FOUNDATION HOSPITAL   (Finland)

^e KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Adiponectin; C reactive protein; Interleukin 1 receptor antagonist; Obesity; Relative weight change

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ADULT; ARTICLE; BLOOD LEVEL; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHILD; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OBESITY; POPULATION; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE;

ADIPONECTIN; BODY MASS INDEX; C-REACTIVE PROTEIN; CHILD; FEMALE; GROWTH; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; MIDDLE AGED;

EID: 37849048243     PISSN: 14791641     EISSN: None     Source Type: Journal    
DOI: 10.3132/dvdr.2007.060     Document Type: Article

References (32)

1. Reaven GM. Banting Lecture 1988: role of insulin resistance in human diabetes. Diabetes 1988;37:1595-607.
2. Trayhurn P, Beattie JH. Physiological role of adipose tissue: white adipose tissue as endocrine and secretory organ. Proc Nutr Soc 2001;60:329-39.
3. Weyer C, Funahashi T, Tanaka S et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86:1930-5.
4. Kumada M, Kihara S, Sumitsuji S et al. for Osaka CAD Study Group. Coronary artery disease. Association of hypoadiponectinemia with coronary artery disease in men. Arterioscler Thromb Vasc Biol 2003;23(1):85-9.
5. Bacha F, Saad R, Gungor N, Arslanian SA. Adiponectin in youth: relationship to visceral adiposity, insulin sensitivity, and beta-cell function. Diabetes Care 2004;27:547-52.
6. Wang Y, Lam KS, Xu JY et al. Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J Biol Chem 2005;280:18341-7.
7. Yudkin JS, Kumari M, Humpries SE, Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? Atherosclerosis 1999;148:209-14.
8. Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003;24:278-301.
9. Pearson TA, Mensah GA, Alexander RW et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
10. Verma S, Yeh ET. C-reactive protein and atherothrombosis - beyond a biomarker: an actual partaker of lesion formation. Am J Physiol Regul Integr Comp Physiol 2003;285:R1253-R1256.
11. Laaksonen DE, Niskanen L, Nyyssönen K et al. C-reactive protein and development of the metabolic syndrome and diabetes in middle-aged men. Diabetologia 2004;47:1403-10.
12. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-54.
13. Salmenniemi U, Ruotsalainen E, Pihlajamäki J et al. Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome. Circulation 2004;110:3842-8.
14. Patti G, D'Ambrosio A, Dobrina A et al. Interleukin-1 receptor antagonist: a sensitive marker of instability in patients with coronary artery disease. J Thromb Thrombolysis 2002;14:139-43.
15. Pietrobelli A, Faith MS, Allison DB, Gallagher D, Chiumello G, Heymsfield SB. Body mass index as a measure of adiposity among children and adolescents: a validation study. J Pediatr 1998;132:204-10.
16. Bellizzi MC, Dietz WH. Workshop on childhood obesity: summary of the discussion. Am J Clin Nutr 1999;70:173S-175S.
17. Warren M, Schreiner PJ, Terry JG. The relation between visceral fat measurement and torso level - is one level better than another? The Atherosclerosis Risk in Communities Study, 1990-1992. Am J Epidemiol 2006;163:352-8.
18. Westerbacka J, Cornér A, Tiikkainen M et al. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia 2004;47:1360-9.
19. Thorand B, Baumert J, Döring A et al. Sex differences in the relation of body composition to markers of inflammation. Atherosclerosis 2006;184:216-24.
20. Maedler K, Sergeev P, Ris F et al. Glucose-induced beta-cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002;110:851-60.
21. Meier CA, Bobbioni E, Gabay C, Assimacopoulos-Jeannet F, Golay A, Dayer JM. IL-1 receptor antagonist serum levels are increased in human obesity: a possible link to the resistance to leptin? J Clin Endocrinol Metab 2002;87:1184-8.
22. Juge-Aubry CE, Somm E, Giusti V et al. Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and inflammation. Diabetes 2003;52:1104-10.
23. Ruotsalainen E, Salmenniemi U, Vauhkonen I et al. Changes in inflammatory cytokines are related to impaired glucose tolerance in offspring of type 2 diabetic subjects. Diabetes Care 2006;29:2714-20.
24. Arend WP, Gabay C. Physiologic role of interleukin-1 receptor antagonist. Arthritis Res 2000;2:245-8.
25. Larsen CM, Faulenbach M, Vaag A et al. Interleukin-1 receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007;356: 1517-26.
26. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006;6:772-83.
27. Weyer C, Funahashi T, Tanaka S et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86:1930-5.
28. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004;291:1730-7.
29. Narayan KMV, Boyle J, Thompson TJ, Gregg EW, Williamson DF. Effect of BMI on lifetime risk for diabetes in the US. Diabetes Care 2007;30:1562-6.
30. Matsubara M, Namioka K, Katayose S. Decreased plasma adiponectin concentrations in women with low-grade C-reactive protein elevation. Eur J Endocrinol 2003;148:657-62.
31. Engström G, Hedblad B, Stavenow L, Lind P, Janzon L, Lindgärde F. Inflammation-sensitive plasma proteins are associated with future weight gain. Diabetes 2003;52:2097-101.
32. Vozarova B, Stefan N, Lindsay RS et al. Low plasma adiponectin concentrations do not predict weight gain in humans. Diabetes 2002;51:2964-7.